Jennison Associates
MRNA icon

Jennison Associates’s Moderna MRNA Stock Holding History

Jennison Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,579
Closed -$3.03M – 669
2022
Q1 		$3.03M Buy
17,579
+12,426
+241% +$2.09M ﹤0.01% 471
2021
Q4 		$1.31M Buy
5,153
+2,816
+120% +$823K ﹤0.01% 586
2021
Q3 		$899K Sell
2,337
-14,030
-86% -$5.17M ﹤0.01% 629
2021
Q2 		$3.85M Buy
+16,367
New +$2.92M ﹤0.01% 518

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates's MRNA Position: Q2 2022 in Review

Jennison Associates sold out of Moderna (MRNA) in Q2 2022, closing a stake of 17,579 shares — an estimated $3.03M sold.

Jennison Associates first reported a position in MRNA in Q2 2021 and held it in 4 quarters. The position peaked at $3.85M in Q2 2021. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Jennison Associates reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
  • Jennison Associates sold 17,579 Moderna shares in Q2 2022, an estimated $3.03M.
  • Jennison Associates first reported a position in Moderna in Q2 2021 and held it in 4 quarters.
  • Jennison Associates's Moderna position peaked at $3.85M in Q2 2021.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Jennison Associates's 13F filing for Q2 2022, filed 2 Aug 2022.